The father had been caring the child since October 2022, and during that time the child was seen several times by medical staff for apparent non-accidental trauma.
The global tissue engineered skin substitute market is projected to grow from USD 2.4 billion in 2024 to USD 3.5 billion by 2034, at a CAGR of 3.9%. The rising demand for advanced wound care solutions ...
Virpax Pharmaceuticals, Inc. ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) ...
Virpax Pharmaceuticals shares are up 59.4% after announcing an extended collaboration with NCATS to advance its NES100 pain management candidate. Virpax also announced results from a minipig Dose ...
Chronic? It’s an acute thing. It happens at a house, and people are brought in ... You are the family medicine doctor. You are the wound care specialist. You are just a person who’s listening to all ...
ProgenaCare's innovative approach to wound care leverages scientific advancements in biomaterials to deliver effective products for a range of wound types, from acute injuries to chronic conditions.
BioStem expects to finalize definitive agreements within 60 days following customary due diligence. The transaction is subject to regulatory approvals and Board consent. BioStem and ProgenaCare will ...